Paroxetine
| Evidence Level: L5 | Predicted Indications: 1 |
Table of Contents
Paroxetine: From Unspecified Original Indication to Ohdo Syndrome and Variants
One-Sentence Summary
Paroxetine’s original approved indication and mechanism of action are not available in the current dataset. The TxGNN model predicts a possible link to Ohdo Syndrome and Variants, a rare genetic disorder, but this prediction is supported by no clinical trials and no published literature — it is a model-only signal.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available in current dataset |
| Predicted New Indication | Ohdo Syndrome and Variants |
| TxGNN Prediction Score | 99.11% |
| Evidence Level | L5 |
| UK Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data for Paroxetine is not currently available in this evidence pack. The prediction rationale notes that Paroxetine belongs to the SSRI (selective serotonin reuptake inhibitor) class, which acts via serotonin reuptake inhibition.
Ohdo syndrome and its variants are rare genetic disorders caused by mutations in genes such as KAT6B or MED12, characterised by ptosis, developmental delay, and skeletal abnormalities. There is no known biological or pharmacological relationship between serotonergic mechanisms and the genetic pathways underlying Ohdo syndrome.
Although the TxGNN score of 0.991 is very high, this is a pure knowledge-graph link prediction with no supporting mechanistic hypothesis, clinical trial, or literature evidence. The prediction is assessed as a potential noise link rather than a credible repurposing signal, and should not be treated as a genuine candidate without further mechanistic investigation.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
Safety Considerations
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
Note: TFDA/MHRA labelled warnings and contraindications data are currently unavailable (marked as a Blocking data gap), which prevents this candidate from progressing to an initial safety assessment (S1) stage.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is supported only by an L5 (model-only) evidence level, with no clinical trials, no literature, and no plausible mechanistic link between Paroxetine’s SSRI activity and Ohdo syndrome’s genetic aetiology. The evidence pack itself flags this as a likely noise link rather than a genuine repurposing signal.
To proceed, the following is needed:
- Confirmed mechanism of action (MOA) data for Paroxetine
- TFDA/MHRA labelled warnings and contraindications (currently a blocking data gap)
- Any preclinical or mechanistic rationale connecting serotonergic activity to Ohdo syndrome pathophysiology
- Independent literature or case evidence before further evaluation is warranted
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.